Amylyx Pharmaceuticals (AMLX) stock is in focus after the company reported that its Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia met its primary and all secondary endpoints with clinically meaningful reductions in hypoglycemic events.
The avexitide news lands after a sharp run in Amylyx Pharmaceuticals’ share price. The company has a 30 day share price return of 66.17% and a year to date share price return of 195.53%, while the 1 year total shareholder return of 259.81% points to strong long term momentum despite a recent 7 day share price pullback of 11.53% and a 1 day decline of 2.85%. This likely reflects investors reassessing risk and digesting the recent follow on equity offering at a discount to the current US$33.75 share price.
Ride the momentum in Amylyx Pharmaceuticals and this avexitide milestone by scanning a hand-picked 19 high quality undiscovered gems that share strong fundamentals and potential catalysts.After the rapid share price move in Amylyx Pharmaceuticals and the recent equity raise, the story now hinges on valuation. Does the current price still leave enough upside to justify the clinical and financing risks from here?
Most Popular Narrative: 32.1% Overvalued
The most followed narrative puts Amylyx Pharmaceuticals’ fair value at $25.56 compared with the last close at $33.75. This comparison highlights a clear valuation gap for anyone focused on avexitide and the broader pipeline.
The company is targeting post bariatric hypoglycemia, a condition with no FDA approved therapies and an estimated 160,000 patients in the U.S. This creates room for a first approved product like avexitide to establish a new revenue line if pricing and access are secured.
Analysts behind this narrative are not just plugging in generic growth curves. They are tying a projected revenue ramp, higher future margins and a premium profit multiple to a single first in class opportunity. This raises the question of which assumptions need to hold for that math to support the current fair value.
Result: Fair Value of $25.56 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the narrative around Amylyx Pharmaceuticals can shift quickly if the single pivotal LUCIDITY trial disappoints, or if future capital raises dilute existing shareholders.
Find out about the key risks to this Amylyx Pharmaceuticals narrative.
Another View on Amylyx Pharmaceuticals Valuation
The analyst narrative points to Amylyx Pharmaceuticals trading about 32.1% above a fair value estimate of $25.56. Our DCF model tells a very different story. It suggests the stock is trading about 83.2% below an implied future cash flow value of $201.25, which is a large gap to interpret.
This kind of spread shows how sensitive outcomes are to assumptions about avexitide, the broader pipeline and dilution. It leaves investors weighing which framework feels more realistic for Amylyx Pharmaceuticals, and which scenario they are comfortable owning.
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Amylyx Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
If this mix of enthusiasm and caution around Amylyx Pharmaceuticals feels familiar, act fast and review the underlying data yourself so you own your conclusion. To help frame both sides of the argument, start with the 2 key rewards and 4 important warning signs.
Looking for more investment ideas beyond Amylyx Pharmaceuticals?
If you want to build on what you have learned from Amylyx Pharmaceuticals, use the Simply Wall St screener to quickly spot other opportunities before they move.
- Target companies with strong balance sheets and resilient fundamentals by reviewing the list of solid balance sheet and fundamentals (52 results).
- Hunt for quality at a potential discount by scanning the 45 high quality undervalued stocks.
- Prioritise stability and sleep better at night by focusing on the 74 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com